Cargando…

THU586 Lipid Species In Non-alcoholic Fatty Liver Disease (NAFLD) In Type 1 Diabetes

Disclosure: A. Taiwo: None. H. Thakker: None. J. Maschek: None. J. Cox: None. S. Summers: Owner/Co-Owner; Self; Centaurus Therapeutics. D. Jalal: None. W. Sivitz: None. A. Dokun: None. B. Chaurasia: None. Background: Non-alcoholic fatty liver disease (NAFLD) is characterized by steatosis at an early...

Descripción completa

Detalles Bibliográficos
Autores principales: Taiwo, Adeyinka, Thakker, Himani, Maschek, John, Cox, James, Summers, Scott, Jalal, Diana, Sivitz, William, Dokun, Ayotunde, Chaurasia, Bhagirath
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10554222/
http://dx.doi.org/10.1210/jendso/bvad114.584
_version_ 1785116360889597952
author Taiwo, Adeyinka
Thakker, Himani
Maschek, John
Cox, James
Summers, Scott
Jalal, Diana
Sivitz, William
Dokun, Ayotunde
Chaurasia, Bhagirath
author_facet Taiwo, Adeyinka
Thakker, Himani
Maschek, John
Cox, James
Summers, Scott
Jalal, Diana
Sivitz, William
Dokun, Ayotunde
Chaurasia, Bhagirath
author_sort Taiwo, Adeyinka
collection PubMed
description Disclosure: A. Taiwo: None. H. Thakker: None. J. Maschek: None. J. Cox: None. S. Summers: Owner/Co-Owner; Self; Centaurus Therapeutics. D. Jalal: None. W. Sivitz: None. A. Dokun: None. B. Chaurasia: None. Background: Non-alcoholic fatty liver disease (NAFLD) is characterized by steatosis at an early stage, which can progress over the years to nonalcoholic steatohepatitis (NASH) and cirrhosis. Steatosis is composed of various lipid species which is derived from influx of monounsaturated and polyunsaturated fatty acids, saturated fats, into the liver caused by peripheral lipolysis in adipocytes and de novo lipogenesis. It is estimated that 20-30% patients with NAFLD will progress to NASH. Hepatic lipotoxicity and inflammation are two key factors that drive the progression of NAFLD to NASH. The presence of NASH increases the risk of cardiovascular events, cirrhosis, hepatocellular cancer and non-liver malignancies. Objective: To determine the association of lipid species with NAFLD in individuals with Type 1 diabetes. Study Design: Thirty individuals with Type 1 diabetes were recruited from our diabetes Clinic at University of Iowa Hospital & Clinics. Participants in this cross-sectional study were categorized into two groups based on the results of a FibroScan, an elastography technique that quantifies liver fat and stiffness. Classification as cases (n = 16) or controls (n = 14) was assigned based on the presence or absence of evidence for NAFLD respectively. The participants came in for a single visit where fasting plasma was drawn for lipidomics analysis by liquid chromatography-tandem mass spectrometry (LC-MS/MS). In total thirty-three lipid species belonging to four different lipid classes: sphingolipids (dihydroceramides, ceramides, dihydrosphingomyelin, sphingomyelin, hexosylceramide), diacylglycerol, phosphatidylcholine and triacylglycerols were analyzed via targeted lipidomics. Results: The BMI was significantly higher in the cases than controls (P = 0.002) and the cases used significantly higher 24 hr insulin doses than controls (P = 0.004). The cases displayed significantly higher circulating levels of total ceramides (p=0.02), diacylglycerol (P= 0.0003) and triacylglycerols (P=0.0003). The two groups displayed similar levels of hexosylceramide, dihydrosphingomyelin, sphingomyelin and phosphatidylcholine. Similar to previous findings numerous sphingolipid species, diacylglycerol and triacylglycerols were found to be positively correlated with BMI. In addition, they were found to be positively correlated with 24hrs insulin dose. Importantly, total circulating dihydroceramide, ceramide, diacylglycerol and triacylglycerols levels were significantly corelated with steatosis score (P = <0.05). None of the lipid species correlated with the fibrosis score. Conclusion: These results suggest that Type 1 diabetes individuals with NAFLD have a higher BMI and display elevated circulating levels of dihydroceramides, ceramides, diacylglycerol and triacylglycerols that are strongly associated with the development of fatty liver disease. Presentation: Thursday, June 15, 2023
format Online
Article
Text
id pubmed-10554222
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-105542222023-10-06 THU586 Lipid Species In Non-alcoholic Fatty Liver Disease (NAFLD) In Type 1 Diabetes Taiwo, Adeyinka Thakker, Himani Maschek, John Cox, James Summers, Scott Jalal, Diana Sivitz, William Dokun, Ayotunde Chaurasia, Bhagirath J Endocr Soc Cardiovascular Endocrinology Disclosure: A. Taiwo: None. H. Thakker: None. J. Maschek: None. J. Cox: None. S. Summers: Owner/Co-Owner; Self; Centaurus Therapeutics. D. Jalal: None. W. Sivitz: None. A. Dokun: None. B. Chaurasia: None. Background: Non-alcoholic fatty liver disease (NAFLD) is characterized by steatosis at an early stage, which can progress over the years to nonalcoholic steatohepatitis (NASH) and cirrhosis. Steatosis is composed of various lipid species which is derived from influx of monounsaturated and polyunsaturated fatty acids, saturated fats, into the liver caused by peripheral lipolysis in adipocytes and de novo lipogenesis. It is estimated that 20-30% patients with NAFLD will progress to NASH. Hepatic lipotoxicity and inflammation are two key factors that drive the progression of NAFLD to NASH. The presence of NASH increases the risk of cardiovascular events, cirrhosis, hepatocellular cancer and non-liver malignancies. Objective: To determine the association of lipid species with NAFLD in individuals with Type 1 diabetes. Study Design: Thirty individuals with Type 1 diabetes were recruited from our diabetes Clinic at University of Iowa Hospital & Clinics. Participants in this cross-sectional study were categorized into two groups based on the results of a FibroScan, an elastography technique that quantifies liver fat and stiffness. Classification as cases (n = 16) or controls (n = 14) was assigned based on the presence or absence of evidence for NAFLD respectively. The participants came in for a single visit where fasting plasma was drawn for lipidomics analysis by liquid chromatography-tandem mass spectrometry (LC-MS/MS). In total thirty-three lipid species belonging to four different lipid classes: sphingolipids (dihydroceramides, ceramides, dihydrosphingomyelin, sphingomyelin, hexosylceramide), diacylglycerol, phosphatidylcholine and triacylglycerols were analyzed via targeted lipidomics. Results: The BMI was significantly higher in the cases than controls (P = 0.002) and the cases used significantly higher 24 hr insulin doses than controls (P = 0.004). The cases displayed significantly higher circulating levels of total ceramides (p=0.02), diacylglycerol (P= 0.0003) and triacylglycerols (P=0.0003). The two groups displayed similar levels of hexosylceramide, dihydrosphingomyelin, sphingomyelin and phosphatidylcholine. Similar to previous findings numerous sphingolipid species, diacylglycerol and triacylglycerols were found to be positively correlated with BMI. In addition, they were found to be positively correlated with 24hrs insulin dose. Importantly, total circulating dihydroceramide, ceramide, diacylglycerol and triacylglycerols levels were significantly corelated with steatosis score (P = <0.05). None of the lipid species correlated with the fibrosis score. Conclusion: These results suggest that Type 1 diabetes individuals with NAFLD have a higher BMI and display elevated circulating levels of dihydroceramides, ceramides, diacylglycerol and triacylglycerols that are strongly associated with the development of fatty liver disease. Presentation: Thursday, June 15, 2023 Oxford University Press 2023-10-05 /pmc/articles/PMC10554222/ http://dx.doi.org/10.1210/jendso/bvad114.584 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of the Endocrine Society. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Cardiovascular Endocrinology
Taiwo, Adeyinka
Thakker, Himani
Maschek, John
Cox, James
Summers, Scott
Jalal, Diana
Sivitz, William
Dokun, Ayotunde
Chaurasia, Bhagirath
THU586 Lipid Species In Non-alcoholic Fatty Liver Disease (NAFLD) In Type 1 Diabetes
title THU586 Lipid Species In Non-alcoholic Fatty Liver Disease (NAFLD) In Type 1 Diabetes
title_full THU586 Lipid Species In Non-alcoholic Fatty Liver Disease (NAFLD) In Type 1 Diabetes
title_fullStr THU586 Lipid Species In Non-alcoholic Fatty Liver Disease (NAFLD) In Type 1 Diabetes
title_full_unstemmed THU586 Lipid Species In Non-alcoholic Fatty Liver Disease (NAFLD) In Type 1 Diabetes
title_short THU586 Lipid Species In Non-alcoholic Fatty Liver Disease (NAFLD) In Type 1 Diabetes
title_sort thu586 lipid species in non-alcoholic fatty liver disease (nafld) in type 1 diabetes
topic Cardiovascular Endocrinology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10554222/
http://dx.doi.org/10.1210/jendso/bvad114.584
work_keys_str_mv AT taiwoadeyinka thu586lipidspeciesinnonalcoholicfattyliverdiseasenafldintype1diabetes
AT thakkerhimani thu586lipidspeciesinnonalcoholicfattyliverdiseasenafldintype1diabetes
AT maschekjohn thu586lipidspeciesinnonalcoholicfattyliverdiseasenafldintype1diabetes
AT coxjames thu586lipidspeciesinnonalcoholicfattyliverdiseasenafldintype1diabetes
AT summersscott thu586lipidspeciesinnonalcoholicfattyliverdiseasenafldintype1diabetes
AT jalaldiana thu586lipidspeciesinnonalcoholicfattyliverdiseasenafldintype1diabetes
AT sivitzwilliam thu586lipidspeciesinnonalcoholicfattyliverdiseasenafldintype1diabetes
AT dokunayotunde thu586lipidspeciesinnonalcoholicfattyliverdiseasenafldintype1diabetes
AT chaurasiabhagirath thu586lipidspeciesinnonalcoholicfattyliverdiseasenafldintype1diabetes